ABSTRACT
Background Treatment guidelines are developed and updated according to evidence-based research. Healthcare workers in the public health sector are responsible for the implementation of said guidelines. The multi-drug resistant tuberculosis (MDR-TB) guideline has undergone major changes over the past 5 years. These changes included shorter treatment regimens and the introduction of novel drugs. These changes have consequently impacted the management of MDR-TB patients.
Objectives To establish healthcare workers’ perspectives on the MDR-TB guidelines and managing patients with MDR-TB.
Methods Healthcare workers employed in MDR-TB departments at Murchison District Hospital in KwaZulu-Natal were invited to complete a written questionnaire. These healthcare workers comprised of doctors, nurses, pharmacists, and data capturers. The questionnaire consisted of both open- and closed-ended questions. Descriptive statistics were generated for closed-ended questions using SPSS (version 25). Open-ended questions were transcribed onto Microsoft Excel and analyzed for common and emerging themes.
Results There were 44 staff employed in the inpatient and outpatient MDR-TB unit. Thirty-four of participants agreed to participate in the questionnaire. HIV co-infection was highlighted as a contributor to complicating the management of MDR-TB patients. The most common co-morbidities associated with MDR-TB patients were diabetes, anaemia and hypertension. The socioeconomic influence on outcomes were highlighted throughout patient responses.
Conclusion The MDR-TB program has come been progressive in its approach to gaining control over MDR-TB. The SBR is an effective regimen with a few safety concerns. The nature of ADRs associated with the regimen are serious with myelosuppression highlighted as a common ADR. The impact of socio-economic factors on treatment outcomes is an important factor that should be considered in addition to MDR-TB regimens. The BPaL regimen may offer benefits of a shorter duration and reduced pill burden but there are concerns over the safety of the regimen. The success of the MDR-TB program requires a holistic approach combining patient factors with an effective, safe and convenient regimen.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The author(s) received no specific funding for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
BREC BREC/00002065/2020
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Not Applicable
Footnotes
Oosthuizenf{at}ukzn.ac.za, Bangalee{at}ukzn.ac.za
Data Availability
All relevant data are within the manuscript and its Supporting Information files.
